Study of the Role of Soluble Inhibitor of Interleukin 22, Interleukin 22 Binding Protein (IL-22BP), in Chronic Inflammatory Bowel Disease

IL-22 is an IL-10 family cytokine that plays major actions to increase intestinal epithelial barrier function and regeneration during experimental colitis. IL-22 binding protein is a small, soluble, and secreted protein potently inhibiting IL-22 actions through preventing the binding with IL-22 Recepteur. This study aims at characterizing how IL-22 binding protein is regulated in Inflammatory bowel disease to better understand the way IL-22 acts on epithelial cells during flares of the disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Inflammatory Bowel Disease Digestive System Diseases Gastroenteritis Gastrointestinal Diseases Inflammatory Bowel Diseases Intestinal Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU de Nantes

Nantes, 44093, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Crohn's disease or Ulcerative colitis
Healthy controls paired for age and sex
Samples availability in the biobank
Signed consent
No (Immune Mediated Inflammatory Disorders other than Inflammatory bowel disease
No other conditions predicted or known to affect IL-22/IL-22 recepteur /IL-22 binding protein regulation
Availability of clinical data
Age >18 y.o.
No pregnancy

Treatment and study plan

Non interventional study

Other

Primary outcomes

Regulation of Interleukine 22 binding protein expression in Crohn's disease or Ulcerative colitis

Time frame: 1 day

Sponsors and collaborators

Lead sponsor

Nantes University Hospital

Other

Registry information

Acronym: IL-22BP MICI

Important dates

Study start: 2014
Primary completion: 2022
Study completion: 2022
First posted: Jul 27, 2016
Registry last updated: Jun 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed